Sumit K. Subudhi, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses the initial results from a phase II study of nivolumab plus ipilimumab in the treatment of metastatic castration-resistant prostate cancer (Abstract 142).
Craig R. Nichols, MD, of the Testicular Cancer Commons and the SWOG Group Chair's Office, discusses the superior outcomes obtained at high-volume centers, the impracticality of referring all patients to such centers, and the international efforts to develop virtual collaborations on salvage management and post-chemotherapy surgery.
Howard I. Scher, MD, of Memorial Sloan Kettering Cancer Center, discusses circulating tumor cell number as a transitional surrogate endpoint for survival in phase II trials on metastatic castration-resistant prostate cancer (Abstract 143).
Nicholas J. van As, MD, of The Royal Marsden NHS Foundation Trust, discusses an analysis of acute toxicity in the PACE-B study, which compared stereotactic body radiotherapy with conventionally fractionated or moderately hypofractionated external-beam radiotherapy for localized prostate cancer (Abstract 1).
Sumanta K. Pal, MD, of City of Hope, who served as a Co-Executive Editor of the 2019 publication Clinical Cancer Advances, discusses progress made during the past year in research and policy. The report was compiled with a team of experts in oncology subspecialties, cancer prevention, quality care, health disparities, and tumor biology.
